Alzheimer’s disease

aan-2025-highlights

Apr 25, 2025

Late-Breaking Science at AAN 2025: Shaping the Future of Neurology

ad-pd-2025-conference-highlights

Apr 18, 2025

Groundbreaking Alzheimer’s Therapies: From Pipeline to Patient Care

pharma-news-for-amgen-novartis-biogen

Apr 08, 2025

Amgen’s UPLIZNA Wins First FDA Nod for IgG4-Related Disease; Aldeyra Gets FDA CRL for Reproxalap in Dry Eye; Novartis’ Vanrafia Snags Accelerated FDA OK for IgAN Proteinuria; Biogen’s BIIB080 Earns Fast Track for Alzheimer’s; Epicrispr’s EPI-321 Cleared by FDA for FSHD

Alzheimer’s Treatment Latest Breakthroughs and Advancements in Therapeutic Development

Feb 26, 2025

Alzheimer’s Treatment: Latest Breakthroughs and Advancements in Therapeutic Development

Semaglutide A Potential Game-Changer in Reducing Alzheimer's Disease Risk

Feb 12, 2025

Semaglutide: A Potential Game-Changer in Reducing Alzheimer’s Disease Risk

Challenges in the Pursuit of Alzheimer’s Disease Treatment Breakthroughs

Feb 12, 2025

Challenges in the Pursuit of Alzheimer’s Disease Treatment Breakthroughs: Drug Clinical Trial Failures

Can Remternetug Solve the Puzzle of Alzheimer’s

Feb 12, 2025

Can Remternetug Solve the Puzzle of Alzheimer’s?

What is the link between Alzheimer’s and Menopause

Feb 12, 2025

What is the Link Between Alzheimer’s and Menopause?

Exploring the Current Alzheimer's Disease Drug Development Pipeline

Feb 12, 2025

Exploring the Current Alzheimer’s Disease Drug Development Pipeline

LEQEMBI A New Hope for Alzheimer’s Disease Patients

Feb 12, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper